{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:26:01Z","timestamp":1791300361551,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Minufiya University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Circulating platelet-derived growth factor receptor-\u03b2 (PDGFR\u03b2) has recently been found to correlate with severity of liver disease in multiple etiologies, including liver steatosis. In diabetic patients with metabolic-associated fatty liver disease (MAFLD), widely used non-invasive scoring systems, particularly the fibrosis-4 (FIB-4) score, showed unsatisfactory performance in predicting liver fibrosis severity. The aim of this study was to evaluate the productivity of serum PDGFR\u03b2 as a non-invasive biomarker of liver fibrosis in diabetic MAFLD patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This was a population-based case-control study conducted on 50 diabetic MAFLD patients, 40 nondiabetic MAFLD patients, and 40 healthy controls. All subjects underwent complete history taking, clinical examination, anthropometric measurements, bioelectrical impedance analysis (BIA), and laboratory tests, including the PDGFR\u03b2 assay. Hepatic steatosis was assessed with magnetic resonance imaging (MRI), along with magnetic resonance elastography (MRE) for the assessment of liver fibrosis. The diagnostic performance of PDGFR\u03b2 as well as PDGFR\u03b2\u2009+\u2009FIB-4 in prediction of significant liver fibrosis in diabetic MAFLD patients was assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Liver steatosis and significant liver fibrosis (\u2265\u2009F2) were significantly higher in diabetic MAFLD patients than in nondiabetics. PDGFR\u03b2 levels were significantly higher in both diabetic and nondiabetic MAFLD patients compared to controls. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of PDGFR\u03b2 to predict significant liver fibrosis in diabetic MAFLD patients were 85%, 93.33%, 89.5%, and 90.3%, respectively, at a cutoff\u2009&gt;\u20092.54, and were 85.71%, 51.52%, 27.3%, and 94.4% at a cutoff\u2009&gt;\u20091.59 in nondiabetics. Sensitivity, specificity, PPV, and NPV of (PDGFR\u03b2 at a cutoff\u2009&gt;\u20092.54\u2009+\u2009FIB-4 at a cutoff\u2009&gt;\u20091.17) to predict significant liver fibrosis in diabetic MAFLD patients were 100%. PDGFR\u03b2 was the only independent predictor of significant liver fibrosis in diabetic MAFLD (<jats:italic>p<\/jats:italic>\u2009=\u20090.006).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>PDGFR\u03b2 proved efficacy as a noninvasive biomarker in the prediction of significant liver fibrosis (\u2265\u2009F2) in diabetic MAFLD patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12876-024-03542-y","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T18:26:03Z","timestamp":1752776763000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Platelet-derived growth factor receptor-\u03b2 as a non-invasive biomarker for liver fibrosis prediction in Egyptian diabetic patients with metabolic-associated fatty liver disease"],"prefix":"10.1186","volume":"25","author":[{"given":"Hanaa","family":"Badran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Elsabaawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Magdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olfat","family":"Hendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Awaad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maymona Abd El-Wahed","family":"Al-Khalifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1808-7928","authenticated-orcid":false,"given":"Mai","family":"Abozeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"issue":"3","key":"3542_CR1","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.3390\/ijms24032844","volume":"24","author":"X Yin","year":"2023","unstructured":"Yin X, Guo X, Liu Z, et al. Advances in the diagnosis and treatment of non-alcoholic fatty liver disease. Int J Mol Sci. 2023;24(3):2844.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3542_CR2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u20139.","journal-title":"J Hepatol"},{"key":"3542_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejim.2023.11.005","volume":"122","author":"V Lekakis","year":"2024","unstructured":"Lekakis V, Papatheodoridis GV. Natural history of metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med. 2024;122:3\u201310.","journal-title":"Eur J Intern Med"},{"issue":"5","key":"3542_CR4","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41401-022-00874-x","volume":"43","author":"XF Tong","year":"2022","unstructured":"Tong XF, Wang QY, Zhao XY, et al. Histological assessment based on liver biopsy: the value and challenges in NASH drug development. Acta Pharmacol Sin. 2022;43(5):1200\u20139.","journal-title":"Acta Pharmacol Sin"},{"issue":"5","key":"3542_CR5","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.4254\/wjh.v14.i5.1025","volume":"14","author":"N Cianci","year":"2022","unstructured":"Cianci N, Subhani M, Hill T, et al. Prognostic non-invasive biomarkers for all-cause mortality in non-alcoholic fatty liver disease: a systematic review and meta-analysis. World J Hepatol. 2022;14(5):1025\u201337.","journal-title":"World J Hepatol"},{"key":"3542_CR6","doi-asserted-by":"publisher","first-page":"101231","DOI":"10.1016\/j.mam.2023.101231","volume":"95","author":"M Parola","year":"2024","unstructured":"Parola M, Pinzani M. Liver fibrosis in NAFLD\/NASH: from pathophysiology towards diagnostic and therapeutic strategies. Mol Aspects Med. 2024;95:101231.","journal-title":"Mol Aspects Med"},{"issue":"1","key":"3542_CR7","doi-asserted-by":"publisher","first-page":"100596","DOI":"10.1016\/j.jhepr.2022.100596","volume":"5","author":"JV Lazarus","year":"2023","unstructured":"Lazarus JV, Castera L, Mark HE, et al. Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice. JHEP Rep. 2023;5(1):100596.","journal-title":"JHEP Rep"},{"issue":"2","key":"3542_CR8","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3390\/biomedicines11020468","volume":"11","author":"E Vetrano","year":"2023","unstructured":"Vetrano E, Rinaldi L, Mormone A, et al. Non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, and non-viral hepatocarcinoma: pathophysiological mechanisms and new therapeutic strategies. Biomedicines. 2023;11(2):468.","journal-title":"Biomedicines"},{"issue":"5","key":"3542_CR9","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00592-019-01467-7","volume":"57","author":"T Alkayyali","year":"2020","unstructured":"Alkayyali T, Qutranji L, Kaya E, et al. Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease. Acta Diabetol. 2020;57(5):613\u20138.","journal-title":"Acta Diabetol"},{"issue":"4","key":"3542_CR10","doi-asserted-by":"publisher","first-page":"486","DOI":"10.5009\/gnl19173","volume":"14","author":"E Kaya","year":"2020","unstructured":"Kaya E, Bakir A, Kani HT, et al. Simple noninvasive scores are clinically useful to exclude, not predict, advanced fibrosis: a study in Turkish patients with biopsy-proven nonalcoholic fatty liver disease. Gut Liver. 2020;14(4):486\u201391.","journal-title":"Gut Liver"},{"issue":"10","key":"3542_CR11","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1097\/MCG.0000000000001339","volume":"54","author":"A Singh","year":"2020","unstructured":"Singh A, Gosai F, Siddiqui MT, et al. Accuracy of noninvasive fibrosis scores to detect advanced fibrosis in patients with type-2 diabetes with biopsy-proven nonalcoholic fatty liver disease. J Clin Gastroenterol. 2020;54(10):891\u20137.","journal-title":"J Clin Gastroenterol"},{"issue":"44","key":"3542_CR12","first-page":"1","volume":"11","author":"R Eletreby","year":"2021","unstructured":"Eletreby R, Abdellatif Z, Gaber Y, et al. Validity of routine biochemical and ultrasound scores for prediction of hepatic fibrosis and steatosis in NAFLD. Egypt Liver J. 2021;11(44):1\u20130.","journal-title":"Egypt Liver J"},{"issue":"1","key":"3542_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41181-023-00210-6","volume":"8","author":"O Wegrzyniak","year":"2023","unstructured":"Wegrzyniak O, Zhang B, Rokka J, et al. Imaging of fibrogenesis in the liver by [18F]TZ-Z09591, an Affibody molecule targeting platelet derived growth factor receptor \u03b2. EJNMMI Radiopharm Chem. 2023;8(1):23.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"4","key":"3542_CR14","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.2337\/db16-0881","volume":"66","author":"Y Onogi","year":"2017","unstructured":"Onogi Y, Wada T, Kamiya C, et al. PDGFR\u03b2 regulates adipose tissue expansion and glucose metabolism via vascular remodeling in diet-induced obesity. Diabetes. 2017;66(4):1008\u201321.","journal-title":"Diabetes"},{"issue":"6","key":"3542_CR15","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1007\/s00259-023-06577-7","volume":"51","author":"Z Li","year":"2024","unstructured":"Li Z, Yang H, Li X, et al. Platelet-derived growth factor receptor \u03b2-targeted positron emission tomography imaging for the noninvasive monitoring of liver fibrosis. Eur J Nucl Med Mol Imaging. 2024;51(6):1530\u201343.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"3542_CR16","doi-asserted-by":"publisher","first-page":"147916412094211","DOI":"10.1177\/1479164120942119","volume":"17","author":"S Shen","year":"2020","unstructured":"Shen S, Wang F, Fernandez A, et al. Role of platelet-derived growth factor in type II diabetes mellitus and its complications. Diab Vasc Dis Res. 2020;17(7):1479164120942119.","journal-title":"Diab Vasc Dis Res"},{"key":"3542_CR17","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ebiom.2019.04.036","volume":"43","author":"J Lambrecht","year":"2019","unstructured":"Lambrecht J, Verhulst S, Mannaerts I, et al. A PDGFR\u03b2-based score predicts significant liver fibrosis in patients with chronic alcohol abuse, NAFLD and viral liver disease. EBioMedicine. 2019;43:501\u201312.","journal-title":"EBioMedicine"},{"key":"3542_CR18","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejim.2017.03.006","volume":"41","author":"G Gutierrez-Buey","year":"2017","unstructured":"Gutierrez-Buey G, N\u00fa\u00f1ez-C\u00f3rdoba JM, Llavero-Valero M, et al. Is HOMA-IR a potential screening test for non-alcoholic fatty liver disease in adults with type 2 diabetes? Eur J Intern Med. 2017;41:74\u20138.","journal-title":"Eur J Intern Med"},{"issue":"Suppl 2","key":"3542_CR19","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s12072-024-10704-3","volume":"18","author":"Y Fouad","year":"2024","unstructured":"Fouad Y, Alboraie M, Shiha G. Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease. Hepatol Int. 2024;18(Suppl 2):827\u201333.","journal-title":"Hepatol Int"},{"key":"3542_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.diabres.2017.09.002","volume":"132","author":"P Aschner","year":"2017","unstructured":"Aschner P. New IDF clinical practice recommendations for managing type 2 diabetes in primary care. Diabetes Res Clin Pract. 2017;132:169\u201370.","journal-title":"Diabetes Res Clin Pract"},{"key":"3542_CR21","unstructured":"https:\/\/www.tanita.com\/es\/mc-780-old\/. MC-780U Multi frequency Segmental Body Composition Analyzer. Accessed on 13\/5\/2024."},{"issue":"1","key":"3542_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/0009-8981(57)90027-X","volume":"2","author":"F De Ritis","year":"1957","unstructured":"De Ritis F, Coltorti M, Giusti G. An enzymic test for the diagnosis of viral hepatitis: the transaminase serum activities. Clin Chim Acta. 1957;2(1):70\u20134.","journal-title":"Clin Chim Acta"},{"issue":"6","key":"3542_CR23","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43(6):1317\u201325.","journal-title":"Hepatology"},{"issue":"3","key":"3542_CR24","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/hep.24105","volume":"53","author":"ZH Lin","year":"2011","unstructured":"Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to\u2010platelet ratio index for the staging of hepatitis C\u2010related fibrosis: an updated meta\u2010analysis. Hepatology. 2011;53(3):726\u201336.","journal-title":"Hepatology"},{"issue":"7","key":"3542_CR25","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1097\/MEG.0b013e32830dfcb3","volume":"21","author":"TJ Cross","year":"2009","unstructured":"Cross TJ, Rizzi P, Berry PA, et al. King\u2019s score: an accurate marker of cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol. 2009;21(7):730\u20138.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"3542_CR26","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846\u201354.","journal-title":"Hepatology"},{"issue":"1","key":"3542_CR27","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.cgh.2019.05.051","volume":"18","author":"J Ampuero","year":"2020","unstructured":"Ampuero J, Pais R, Aller R, et al. Development and validation of Hepamet Fibrosis Scoring System-A simple, noninvasive test to identify patients with nonalcoholic fatty liver Disease with Advanced Fibrosis. Clin Gastroenterol Hepatol. 2020;18(1):216\u2013e255.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"3542_CR28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1148\/radiol.2491071375","volume":"249","author":"M Bahl","year":"2008","unstructured":"Bahl M, Qayyum A, Westphalen AC, et al. Liver steatosis: investigation of opposed-phase T1-weighted liver MR signal intensity loss and visceral fat measurement as biomarkers. Radiology. 2008;249(1):160\u20136.","journal-title":"Radiology"},{"issue":"5","key":"3542_CR29","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00330-015-3949-z","volume":"26","author":"S Singh","year":"2016","unstructured":"Singh S, Venkatesh SK, Loomba R, et al. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. Eur Radiol. 2016;26(5):1431\u201340.","journal-title":"Eur Radiol"},{"key":"3542_CR30","unstructured":"https:\/\/www.bt-laboratory.com\/index.php\/Shop\/Index\/productPrimacuDetail\/p_id\/25753.html. Human Platelet-Derived Growth Factor Receptor Beta, PDGFRB Primacu\u2122 ELISA Kit. Accessed on 9\/8\/2024."},{"issue":"3","key":"3542_CR31","doi-asserted-by":"publisher","first-page":"e0174291","DOI":"10.1371\/journal.pone.0174291","volume":"12","author":"Y Li","year":"2017","unstructured":"Li Y, Wang J, Tang Y, et al. Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in Chinese population: evidence from the Dongfeng-Tongji cohort study. PLoS ONE. 2017;12(3):e0174291.","journal-title":"PLoS ONE"},{"issue":"10","key":"3542_CR32","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1111\/liv.13739","volume":"38","author":"LC Bertot","year":"2018","unstructured":"Bertot LC, Jeffrey GP, de Boer B, et al. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non\u2010alcoholic fatty liver disease. Liver Int. 2018;38(10):1793\u2013802.","journal-title":"Liver Int"},{"issue":"128","key":"3542_CR33","first-page":"1","volume":"22","author":"J Chen","year":"2022","unstructured":"Chen J, Hu P, Wang Y, et al. Association between type 2 diabetes status and prevalence of liver steatosis and fibrosis among adults aged\u2009\u2265\u200940 years. BMC Endocr Disord. 2022;22(128):1\u20139.","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"3542_CR34","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3350\/cmh.2013.19.2.140","volume":"19","author":"DY Ju","year":"2013","unstructured":"Ju DY, Choe YG, Cho YK, et al. The influence of waist circumference on insulin resistance and nonalcoholic fatty liver disease in apparently healthy Korean adults. Clin Mol Hepatol. 2013;19(2):140\u20137.","journal-title":"Clin Mol Hepatol"},{"issue":"9","key":"3542_CR35","first-page":"1275","volume":"43","author":"B Amirkalali","year":"2014","unstructured":"Amirkalali B, Poustchi H, Keyvani H, et al. Prevalence of non-alcoholic fatty liver disease and its predictors in north of Iran. Iran J Public Health. 2014;43(9):1275\u201383.","journal-title":"Iran J Public Health"},{"issue":"9","key":"3542_CR36","doi-asserted-by":"publisher","first-page":"e39575","DOI":"10.5812\/hepatmon.39575","volume":"16","author":"N Motamed","year":"2016","unstructured":"Motamed N, Rabiee B, Hemasi GR, et al. Body roundness index and waist-to-height ratio are strongly associated with non-alcoholic fatty liver disease: a population-based study. Hepat Mon. 2016;16(9):e39575.","journal-title":"Hepat Mon"},{"issue":"2","key":"3542_CR37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.14218\/JCTH.2017.00004","volume":"5","author":"IH Borai","year":"2017","unstructured":"Borai IH, Shaker Y, Kamal MM, et al. Evaluation of biomarkers in Egyptian patients with different grades of nonalcoholic fatty liver disease. J Clin Translational Hepatol. 2017;5(2):109\u201318.","journal-title":"J Clin Translational Hepatol"},{"issue":"22","key":"3542_CR38","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1097\/CM9.0000000000000503","volume":"132","author":"LD Chen","year":"2019","unstructured":"Chen LD, Huang JF, Chen QS, et al. Validation of fatty liver index and hepatic steatosis index for screening of non-alcoholic fatty liver disease in adults with obstructive sleep apnea hypopnea syndrome. Chin Med J. 2019;132(22):2670\u20136.","journal-title":"Chin Med J"},{"issue":"1","key":"3542_CR39","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.21608\/ejhm.2022.224889","volume":"87","author":"M Kassem","year":"2022","unstructured":"Kassem M, Galal GM, Younis MA, et al. Anthropometric measures as predictors of non-alcoholic fatty liver disease in adult asymptomatic egyptians. Egypt J Hosp Med. 2022;87(1):1400\u20136.","journal-title":"Egypt J Hosp Med"},{"issue":"2","key":"3542_CR40","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40519-014-0146-z","volume":"20","author":"N Vitturi","year":"2015","unstructured":"Vitturi N, Soattin M, De Stefano F, et al. Ultrasound, anthropometry and bioimpedance: a comparison in predicting fat deposition in non-alcoholic fatty liver disease. Eat Weight Disord. 2015;20(2):241\u20137.","journal-title":"Eat Weight Disord"},{"issue":"6","key":"3542_CR41","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1089\/met.2017.0001","volume":"15","author":"YH Ko","year":"2017","unstructured":"Ko YH, Wong TC, Hsu YY, et al. The correlation between body fat, visceral fat, and nonalcoholic fatty liver disease. Metab Syndr Relat Disord. 2017;15(6):304\u201311.","journal-title":"Metab Syndr Relat Disord"},{"issue":"12","key":"3542_CR42","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.cgh.2017.06.030","volume":"15","author":"M Balakrishnan","year":"2017","unstructured":"Balakrishnan M, El-Serag HB, Nguyen T, et al. Obesity and risk of nonalcoholic fatty liver disease: a comparison of bioelectrical impedance analysis and conventionally-derived anthropometric measures. Clin Gastroenterol Hepatol. 2017;15(12):1965\u20137.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"3542_CR43","doi-asserted-by":"publisher","first-page":"e108643","DOI":"10.5812\/semj.108643","volume":"22","author":"Z Hatamizargaran","year":"2021","unstructured":"Hatamizargaran Z, Sasani M, Akhlaghi M. Association of non-alcoholic fatty liver disease with body Fat percentage in normal-weight individuals. Shiraz E-Med J. 2021;22(11):e108643.","journal-title":"Shiraz E-Med J"},{"issue":"1","key":"3542_CR44","doi-asserted-by":"publisher","first-page":"20219","DOI":"10.1038\/s41598-022-23729-1","volume":"12","author":"S Zhang","year":"2022","unstructured":"Zhang S, Wang L, Yu M, et al. Fat mass index as a screening tool for the assessment of non-alcoholic fatty liver disease. Sci Rep. 2022;12(1):20219.","journal-title":"Sci Rep"},{"issue":"4","key":"3542_CR45","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s10620-021-06953-z","volume":"67","author":"S Nobarani","year":"2022","unstructured":"Nobarani S, Alaei-Shahmiri F, Aghili R, et al. Visceral adipose tissue and non-alcoholic fatty liver disease in patients with type 2 diabetes. Dig Dis Sci. 2022;67(4):1389\u201398.","journal-title":"Dig Dis Sci"},{"key":"3542_CR46","doi-asserted-by":"crossref","unstructured":"Tanase DM, Gosav EM, Costea CF et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res. 2020; 2020:3920196.","DOI":"10.1155\/2020\/3920196"},{"key":"3542_CR47","doi-asserted-by":"publisher","first-page":"1221669","DOI":"10.3389\/fmolb.2023.1221669","volume":"10","author":"HJ Park","year":"2023","unstructured":"Park HJ, Choi J, Kim H, et al. Cellular heterogeneity and plasticity during NAFLD progression. Front Mol Biosci. 2023;10:1221669.","journal-title":"Front Mol Biosci"},{"issue":"12","key":"3542_CR48","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.17219\/acem\/106173","volume":"28","author":"R Kempi\u0144ski","year":"2019","unstructured":"Kempi\u0144ski R, \u0141ukawska A, Krzy\u017canowski F, et al. Clinical outcomes of non-alcoholic fatty liver disease: polish-case control study. Adv Clin Exp Med. 2019;28(12):1615\u201320.","journal-title":"Adv Clin Exp Med"},{"issue":"12","key":"3542_CR49","doi-asserted-by":"publisher","first-page":"7640","DOI":"10.4103\/jfmpc.jfmpc_856_22","volume":"11","author":"P Kumar","year":"2022","unstructured":"Kumar P, Rawat S, Kakar A, et al. Prevalence of non-alcoholic fatty liver disease among diabetes, prediabetes and healthy population. J Family Med Prim Care. 2022;11(12):7640\u20133.","journal-title":"J Family Med Prim Care"},{"key":"3542_CR50","doi-asserted-by":"crossref","unstructured":"Zhang J, Zhang R, Wang Y et al. The level of serum albumin is associated with renal prognosis in patients with diabetic nephropathy. J Diabetes Res. 2019; 2019:7825804.","DOI":"10.1155\/2019\/7825804"},{"issue":"7","key":"3542_CR51","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s11883-022-01028-4","volume":"24","author":"A Martin","year":"2022","unstructured":"Martin A, Lang S, Goeser T, et al. Management of dyslipidemia in patients with non-alcoholic fatty liver disease. Curr Atheroscler Rep. 2022;24(7):533\u201346.","journal-title":"Curr Atheroscler Rep"},{"issue":"3","key":"3542_CR52","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1590\/s0004-2803.201900000-51","volume":"56","author":"G Ray","year":"2019","unstructured":"Ray G, Agarwala T. A study of metabolic parameters in non diabetic patients with non alcoholic fatty liver disease-importance of Dyslipidemia. Arq Gastroenterol. 2019;56(3):270\u20135.","journal-title":"Arq Gastroenterol"},{"issue":"2","key":"3542_CR53","doi-asserted-by":"publisher","first-page":"47","DOI":"10.35514\/mtd.2021.47","volume":"13","author":"TS Gams\u0131z","year":"2021","unstructured":"Gams\u0131z TS, K\u00f6ro\u011flu E. Assessment of Hepatosteatosis among Diabetic and nondiabetic Pat\u0131ents using biochemical parameters and noninvasive imaging techniques. Maltepe T\u0131p Dergisi. 2021;13(2):47\u201351.","journal-title":"Maltepe T\u0131p Dergisi"},{"key":"3542_CR54","doi-asserted-by":"publisher","first-page":"615978","DOI":"10.3389\/fmed.2021.615978","volume":"8","author":"LJ Heyens","year":"2021","unstructured":"Heyens LJ, Busschots D, Koek GH, et al. Liver fibrosis in non-alcoholic fatty liver disease: from liver biopsy to non-invasive biomarkers in diagnosis and treatment. Front Med. 2021;8:615978.","journal-title":"Front Med"},{"issue":"10","key":"3542_CR55","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/s41366-021-00881-8","volume":"45","author":"A Drolz","year":"2021","unstructured":"Drolz A, Wolter S, Wehmeyer MH, et al. Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity. Int J Obes. 2021;45(10):2197\u2013204.","journal-title":"Int J Obes"},{"issue":"6","key":"3542_CR56","doi-asserted-by":"publisher","first-page":"e0269070","DOI":"10.1371\/journal.pone.0269070","volume":"17","author":"J Park","year":"2022","unstructured":"Park J, Kwon HJ, Sohn W, et al. Risk of liver fibrosis in patients with prediabetes and diabetes mellitus. PLoS ONE. 2022;17(6):e0269070.","journal-title":"PLoS ONE"},{"issue":"7","key":"3542_CR57","doi-asserted-by":"publisher","first-page":"e38346","DOI":"10.5812\/hepatmon.38346","volume":"16","author":"HI Fallatah","year":"2016","unstructured":"Fallatah HI, Akbar HO, Fallatah AM. Fibroscan compared to FIB-4, APRI, and AST\/ALT ratio for Assessment of Liver Fibrosis in Saudi patients with nonalcoholic fatty liver disease. Hepat Mon. 2016;16(7):e38346.","journal-title":"Hepat Mon"},{"issue":"2","key":"3542_CR58","first-page":"e22682","volume":"14","author":"N Shaji","year":"2022","unstructured":"Shaji N, Singhai A, Sarawagi R, et al. Assessment of Liver Fibrosis using non-invasive screening tools in individuals with diabetes Mellitus and metabolic syndrome. Cureus. 2022;14(2):e22682.","journal-title":"Cureus"},{"issue":"7","key":"3542_CR59","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.4103\/jfmpc.jfmpc_2212_21","volume":"11","author":"M Saran","year":"2022","unstructured":"Saran M, Sharma JK, Ranjan A, et al. A retrospective study to find out the correlation between NAFLD, diabetes, and obesity in Indian patients. J Family Med Prim Care. 2022;11(7):3504\u201310.","journal-title":"J Family Med Prim Care"},{"issue":"6","key":"3542_CR60","doi-asserted-by":"publisher","first-page":"952","DOI":"10.5009\/gnl210391","volume":"16","author":"S Han","year":"2022","unstructured":"Han S, Choi M, Lee B, et al. Accuracy of Noninvasive Scoring systems in assessing liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and Meta-analysis. Gut Liver. 2022;16(6):952\u201363.","journal-title":"Gut Liver"},{"issue":"2","key":"3542_CR61","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","volume":"68","author":"E Vilar-Gomez","year":"2018","unstructured":"Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68(2):305\u201315.","journal-title":"J Hepatol"},{"issue":"5","key":"3542_CR62","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/ajg.2016.453","volume":"112","author":"S McPherson","year":"2017","unstructured":"McPherson S, Hardy T, Dufour JF, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112(5):740\u201351.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"3542_CR63","doi-asserted-by":"publisher","first-page":"100067","DOI":"10.1016\/j.jhepr.2020.100067","volume":"2","author":"K Patel","year":"2020","unstructured":"Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2020;2(2):100067.","journal-title":"JHEP Rep"},{"issue":"14","key":"3542_CR64","doi-asserted-by":"publisher","first-page":"7873","DOI":"10.3390\/ijms25147873","volume":"25","author":"H Akk\u0131z","year":"2024","unstructured":"Akk\u0131z H, Gieseler RK, Canbay A. Liver fibrosis: from Basic Science towards Clinical Progress, focusing on the Central Role of hepatic stellate cells. Int J Mol Sci. 2024;25(14):7873.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3542_CR65","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/sjg.sjg_357_21","volume":"28","author":"Y Fouad","year":"2022","unstructured":"Fouad Y, Esmat G, Elwakil R, et al. The Egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Saudi J Gastroenterol. 2022;28(1):3\u201320.","journal-title":"Saudi J Gastroenterol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03542-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-024-03542-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03542-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T14:06:16Z","timestamp":1757253976000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-024-03542-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3542"],"URL":"https:\/\/doi.org\/10.1186\/s12876-024-03542-y","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"8 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the National Liver Institute Ethics Committee (Protocol number 00227\/2020) and was carried out in conformity with the Declaration of Helsinki. Each participant provided written informed consent for participation in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"524"}}